Stay updated on Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.

Latest updates to the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4, signaling a content update to the study details page.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now displays Revision: v3.6.3, replacing the previous v3.6.1 as the study document version. This appears to be an administrative update that does not modify core study content.SummaryDifference0.0%

- Check39 days agoChange DetectedThe page revision tag was updated from v3.6.0 to v3.6.1, signaling a small build update. The study content and visible information remain unchanged.SummaryDifference0.0%

- Check54 days agoChange DetectedThe study record now shows recruitment is closed to new participants, and new recruitment sites (e.g., Hunan Cancer hospital 1 and University College Hospital) along with updated navigation items were added to aid readers in understanding how to join and read the study.SummaryDifference0.3%

- Check61 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, indicating a new version of the study documentation has been issued for the record.SummaryDifference0.0%

- Check75 days agoChange DetectedA new revision entry was added: Revision: v3.5.4, replacing the prior v3.5.3. This indicates a routine update to the Study Details page.SummaryDifference0.0%

Stay in the know with updates to Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.